课题基金 / 基金详情

Stem Cell Transplantation for Hemoglobinopathies in Dogs

Stem Cell Transplantation for Hemoglobinopathies in Dogs
干细胞移植治疗狗的血红蛋白病
批准号:
6690207
负责人:
JOHN E HEARST
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-15 至 2004-01-14

项目摘要

项目成果

JOHN E HEARST的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):骨髓移植有可能完全治愈血红蛋白病的疾病症状。错配(相关-单倍体相合)骨髓移植对镰状细胞病或地中海贫血患者的成功应用要求在骨髓中实现并稳定异源嵌合体,并且发病率和死亡率低于现有错配骨髓移植(BMT)方案中经历的发病率和死亡率。这一目标需要使用更少的全身辐射和更少的药物骨髓消融来支持移植。通过使用经光化学处理的供体白细胞,已经在小鼠中实现并稳定了混合嵌合骨髓状态,所述供体白细胞的增殖能力被阻断,但保留了其免疫活性。在完全MHC错配环境中的小鼠骨髓移植模型实验最近证明,在低剂量清髓性辐射条件下,在不存在清髓性和免疫抑制药物的情况下,S-59(一种紫杉醇)光化学处理(S-59 PCT)的T细胞回加促进和稳定异源嵌合体,大大降低了移植物抗宿主病(GVHD)的风险。在美国公共卫生服务基金R 01 HL 63456“干细胞移植建立全嵌合体”的支持下,该验证完成后,该项目目前正进入开发阶段,最终将导致儿科异基因干细胞移植的临床方案获得批准。这一成功得益于儿童医院奥克兰研究所和Cerus公司之间富有成效的合作。这个合作小组现在得出结论,在儿科患者中获得镰状细胞病或地中海贫血临床试验的最佳方法需要在西雅图的Fred哈钦森医学中心的狗移植模型中进行验证。犬实验将在本SBIR的第II阶段启动。I期将是使用Cerus细胞增殖试验、诱导细胞因子合成试验和诱导表面抗原表达试验对犬白细胞进行S-59光化学处理的体外验证。当发现将犬T细胞增殖降低至未处理犬T细胞的95%所需的光化学条件时,将达到第I阶段的特定目标。这些细胞必须保持活力。
英文摘要
DESCRIPTION (provided by applicant): Bone marrow transplantation has the potential of providing a complete cure of the disease symptoms of hemoglobinopathies. Successful application of mismatched (related-haploidentical) bone marrow transplantation to patients with sickle cell disease or a thalassemia requires that allochimerism be achieved and stabilized in the bone marrow with less morbidity and mortality than are being experienced in existing mismatched bone marrow transplantation (BMT) protocols. This goal requires use of less total body radiation and less drug myeloablation in support of the transplantation. Mixed chimeric bone marrow states have been achieved and stabilized in mice through the use of psoralen photochemically treated donor leukocytes which are blocked in their proliferative capabilities but which retain their immunological activities. Model mouse bone marrow transplantation experiments, in a complete MHC mismatch setting, have recently demonstrated that under low dose myeloablative radiation conditions and in the absence of myeloablative and immunosuppressive drugs, S-59 (a psoralen) photochemically treated (S-59 PCT) T-cell add-backs promote and stabilize allochimerism with greatly reduced risk of graft versus host disease (GVHD). With the completion of this validation through the support of US Public Health Service Grant R01 HL63456 "Stem Cell Transplantation to Establish AIIochimerism," this project is now entering a development phase that should ultimately lead to an approved clinical protocol of pediatric allogeneic stem cell transplantation. This success has resulted from a very productive collaboration between Children's Hospital Oakland Research Institute and Cerus Corporation. This collaborative team has now concluded that the best approach for access to a clinical test in pediatric patients for sickle cell disease or for thalassemia requires a validation in the dog model for transplantation at the Fred Hutchinson Medical Center in Seattle. The dog experiments will be initiated in Phase II of this SBIR. Phase I will be the in vitro validation of the S-59 photochemical treatment of dog leukocytes using the Cerus cell proliferation assay, the induced cytokine synthesis assay, and the induced surface antigen expression assay. The specific aim of Phase I will be met when the photochemical conditions have been found that are required to reduce the dog T-cell proliferation to 95 percent of untreated dog T-cells. These cells must have retained viability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
  • 批准号:
    6787862
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    JOHN E HEARST
  • 依托单位:
MINIATURIZED INSTRUMENTATION FOR THE HTS OF DNA REPAIR
  • 批准号:
    6738364
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    JOHN E HEARST
  • 依托单位:
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
Cord Blood Stem Cell Transplantation, Hemoglobinopathies
  • 批准号:
    6689114
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    JOHN E HEARST
  • 依托单位:
海外基金